Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

How Is The HER2-Negative Breast Cancer Market Expected To Grow In Terms Of Size?

The market size of her2-negative breast cancer has seen significant growth in the recent past. It is projected to increase from $16.29 billion in 2024 to $17.57 billion in 2025, marking a compound annual growth rate (CAGR) of 7.8%. Factors such as the increase in breast cancer instances, heightened awareness concerning breast cancer, surge in healthcare expenditure, an older population, and the growth of healthcare infrastructures are credited for the growth throughout the historic period.

In the coming years, the her2-negative breast cancer market is projected to experience robust growth, expanding to $23.67 billion by 2029 with a compound annual growth rate (CAGR) of 7.7%. This anticipated increase in market size over the forecast period is linked to factors such as rising alcohol and tobacco use, the growing prevalence of obesity, shifting towards unhealthy lifestyles, and the rising demand for efficacious treatment options. Key trends to watch in this time frame comprise breakthroughs in diagnostic technology, the incorporation of targeted and immunotherapies, endorsements from the FDA, and advancements in technology.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21203&type=smp

What Market Forces Are Contributing To The Growth Of The HER2-Negative Breast Cancer Market?

The escalation in instances of breast cancer is set to bolster the growth of the HER2-negative breast cancer market. Indiscriminate growth of irregular cells within the breast tissue, generally beginning in the ducts or lobules, describes the condition of breast cancer. This surge in instances of breast cancer is contributed to by various factors such as heightened awareness and enhanced screening techniques, which leads to early and frequent discovery. HER2-Negative Breast Cancer is pivotal in advancing research on breast cancer by shedding light on unique tumor biology and treatment approaches, which aids in creating more targeted therapies for patients. For instance, the Centers for Disease Control and Prevention, a governmental entity in the US, reported in June 2024 that 272,454 new breast cancer cases were found among women in 2021, while the disease resulted in the death of 42,211 women in 2022. Consequently, the increasing instances of breast cancer cases are propelling the HER2-negative breast cancer market’s expansion.

How Is The HER2-Negative Breast Cancer Market Segmented Across Key Categories?

The her2-negative breast cancermarket covered in this report is segmented –

1) By Treatment Type: Chemotherapy; Hormone Therapy; Targeted Therapy; Immunotherapy

2) By Cancer Stage: Early Stage; Locally Advanced Stage; Metastatic Stage

3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy

Subsegments:

1) By Chemotherapy: Anthracyclines; Taxanes; Platinum-Based Chemotherapy; Alkylating Agents; Antimetabolites

2) By Hormone Therapy: Selective Estrogen Receptor Modulators (SERMs); Aromatase Inhibitors; Selective Estrogen Receptor Degraders (SERDs)

3) By Targeted Therapy: CDK4/6 Inhibitors; PI3K Inhibitors; PARP Inhibitors

4) By Immunotherapy: Immune Checkpoint Inhibitors; Tumor-Infiltrating Lymphocyte (TIL) Therapy

What Current And Upcoming Trends Are Shaping The HER2-Negative Breast Cancer Market?

Major companies in the HER2-negative breast cancer market are working toward gaining regulatory approvals to bring new treatments to market, broaden their therapeutic offerings, and strengthen their position in the industry. Regulatory approvals refer to formal permissions granted by health authorities after a drug meets criteria for safety, efficacy, and quality. For instance, in October 2024, Genentech Inc., a US-based biotechnology company, received FDA approval for Itovebi (inavolisib) as a targeted therapy for advanced hormone receptor-positive (HR+), HER2-negative breast cancer with PIK3CA mutation. The approval enables the use of Itovebi alongside palbociclib and fulvestrant, showing improved progression-free survival compared to existing treatment options. This combination therapy offers a much-needed option for patients with limited alternatives, highlighting the significance of biomarker testing to identify eligible candidates.

Who Are The Major Stakeholders Operating In The HER2-Negative Breast Cancer Market?

Major companies operating in the HER2-negative breast cancer market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, Sanofi S.A., AstraZeneca PLC, Novartis International AG, Eli Lilly and Company, Amgen Inc., Daiichi Sankyo Company Limited, Jiangsu Hansoh Pharmaceutical Co. Ltd., BeiGene Ltd., Chipscreen Biosciences Ltd., F. Hoffmann-La Roche Ltd, PharmAbcine Inc., Adagene Inc., H3 Biomedicine Inc., Radius Health Inc., Zenith Epigenetics Ltd.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/her2-negative-breast-cancer-global-market-report

How Do Regional Dynamics Influence The HER2-Negative Breast Cancer Market Performance?

North America was the largest region in the HER2-negative breast cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the HER2-negative breast cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=21203&type=smp

Browse Through More Reports Similar to the Global HER2-Negative Breast Cancer Market 2025, By The Business Research Company

Breast Implants Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/breast-implants-global-market-report

Breast Pumps Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/breast-pumps-global-market-report

Breast Imaging Technologies Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/breast-imaging-technologies-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model